Nanosonics (ASX:NAN) Shares Ease Today: What Is Keeping the Infection Prevention Stock in Focus?

Sonal Goyal

06 November 2026 06:09 PM AEDT

Nanosonics (ASX:NAN) Shares Ease Today: What Is Keeping the Infection Prevention Stock in Focus?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Nanosonics (ASX:NAN) traded at A$2.89 during the 6 November 2026 session, down 2.03%.
FY26 Revenue was A$203.9 million, up 3%, or 6% in constant currency.
Trophon unit placements rose 9% to 4,230, and cash was A$155.2 million with no debt.

Nanosonics (ASX:NAN) shares were quoted at A$2.89 during the 6 November 2026 trading session, down 2.03%. The S&P/ASX 200 Health Care index (XHJ) eased 0.20% to 35,258.30 during the same session, while the S&P/ASX 200 was down 0.49% at 9,020.80. The session move is not linked to the 25 August 2026 FY26 result. Nanosonics makes the trophon ultrasound probe disinfection system used in hospitals to reduce infection risk.

Latest Developments

FY26 Financial Results (released 25 August 2026)

Nanosonics reported revenue of A$203.9 million, up 3%, or up 6% at constant currency, and EBIT of A$16.0 million, down 10%. Trophon-only EBIT was A$50.6 million, up 5%. Trophon unit placements rose 9% to 4,230, and the installed base grew 6% to 39,230 devices. Record North American upgrades rose 32%. The company completed a A$20 million buyback and held cash of A$155.2 million with no debt.

About the Company

Nanosonics is an ASX-listed medical technology company headquartered in Sydney. Its trophon system is used to disinfect ultrasound probes in hospitals.

Business Overview

Nanosonics earns revenue from trophon systems, placed in hospitals and sold with consumables and services. Its next-generation trophon3 and trophon2 Plus launched in FY26, and the company reports installed base growth and upgrade activity.

Sector Context

The S&P/ASX 200 Health Care Index (XHJ) eased 0.20% to 35,258.30 during the same session, while the S&P/ASX 200 was down 0.49% at 9,020.80. Hospital Capital spending and infection control standards shape Demand for disinfection equipment, and currency affects results reported in Australian dollars.

Risks to Watch

FY26 EBIT fell 10% despite revenue growth, and the company noted the strengthening Australian dollar as a Factor in reported revenue. Hospital capital budgets can delay placements.

Catalysts on Watch

Investors may follow the H1 FY27 result, upgrade activity in North America and the take-up of trophon3.

Final Takeaways

Nanosonics (ASX:NAN) traded lower on 6 November 2026 in a session where the health care index eased. Its FY26 result, released on 25 August 2026, showed higher revenue and a stronger cash position.

FAQs

Q: What was the NAN share price on 6 November 2026?

A: Nanosonics shares were quoted at A$2.89 during the trading session, down 2.03%.

Q: What was FY26 revenue?

A: A$203.9 million, up 3%.

Q: How many trophon units were placed?

A: 4,230, up 9% on the prior corresponding period.

Q: What was EBIT?

A: A$16.0 million, down 10%.

Q: Is the session move linked to the result?

A: No. The result was released on 25 August 2026.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.